Dose-limiting, adverse event-associated bradycardia with ß-blocker treatment of atrial fibrillation in the GENETIC-AF trial.
Heart Rhythm O2
; 3(1): 40-49, 2022 Feb.
Article
in En
| MEDLINE
| ID: mdl-35243434
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Risk_factors_studies
Language:
En
Journal:
Heart Rhythm O2
Year:
2022
Document type:
Article
Country of publication: